APLN and type 2 diabetes mellitus: Long-term apelin-13 administration can prevent pancreatic beta cell loss or dysfunction in type 2 diabetic rat models and reduce myocardial fatty acid uptake and oxidation through inhibiting the PPAR-α receptor (49).